T Rao, MD
Neurology · Charlotte, NCNPI 1023070745
Payments from drug & device makers
What this record shows
This record is dominated by education: $6 of the $6 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Travere Therapeutics, Inc.. That places this record below the midpoint for neurology clinicians in NC, where the typical reported total is $688.
Across 3 payments — averaging $2.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$6
Across 418 payments — averaging $9635.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2M
- UCB SA$558K
- F. Hoffmann-la Roche AG$505K
- Sanofi US Services Inc.$414K
- Janssen Research & Development, LLC$253K
- Roche Products Limited$132K
- plus $199K from 9 others
What the payments were for
- Education$6100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 3 | $6 |
How this compares
$6 in reported general payments places this provider in the 5th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 77 | $2,664,783 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 81 | $1,775,750 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 38 | $1,256,168 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 76 | $1,112,283 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 23 | $608,117 |
| FirdapseAmifampridine Phosphate | 14 | $430,295 |
| Kesimpta PenOfatumumab | 25 | $312,530 |
| RebifInterferon Beta-1a/Albumin | 12 | $126,143 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $96,437 |
| Teriflunomide | 19 | $14,263 |
| BotoxOnabotulinumtoxina | 14 | $10,854 |
| Rivastigmine | 44 | $10,249 |
| Ajovy SyringeFremanezumab-Vfrm | 11 | $8,729 |
| Droxidopa | 21 | $4,388 |
| AmantadineAmantadine Hcl | 84 | $3,494 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charlotte
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Megan DonnellyCharlotte$601K
- Sanjay IyerCharlotte$581K
- Urvi DesaiCharlotte$262K
- Danielle Englert DoggettCharlotte$215K
- Robert WigginsCharlotte$138K
- Ardith CourtneyCharlotte$120K
- Joseph ChipmanCharlotte$118K
- Kurt WashburnCharlotte$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.